678 related articles for article (PubMed ID: 9156803)
21. Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice.
Kircheis R; Küpcü Z; Wallner G; Rössler V; Schweighoffer T; Wagner E
Cancer Gene Ther; 2000 Jun; 7(6):870-8. PubMed ID: 10880017
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
23. Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells.
Koppenhagen FJ; Küpcü Z; Wallner G; Crommelin DJ; Wagner E; Storm G; Kircheis R
Clin Cancer Res; 1998 Aug; 4(8):1881-6. PubMed ID: 9717815
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice.
Sun T; Kim TS; Waltz MR; Cohen EP
Cancer Gene Ther; 1995 Sep; 2(3):183-90. PubMed ID: 8528961
[TBL] [Abstract][Full Text] [Related]
25. In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
Wang G; Tschoi M; Spolski R; Lou Y; Ozaki K; Feng C; Kim G; Leonard WJ; Hwu P
Cancer Res; 2003 Dec; 63(24):9016-22. PubMed ID: 14695220
[TBL] [Abstract][Full Text] [Related]
26. [Interleukin-12 gene transfection into murine B16 melanoma cells suppresses tumorigenicity and decreases metastatic potential].
Fu J; Zheng J; Fang W
Zhonghua Yi Xue Za Zhi; 1998 Aug; 78(8):627-9. PubMed ID: 11038817
[TBL] [Abstract][Full Text] [Related]
27. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice.
Lasek W; Golab J; Maśliński W; Switaj T; Bałkowiec EZ; Stokłosa T; Giermasz A; Malejczyk M; Jakóbisiak M
Eur Cytokine Netw; 1999 Sep; 10(3):345-56. PubMed ID: 10477391
[TBL] [Abstract][Full Text] [Related]
28. [Antitumor effect of M-CSF and/or IFN-gamma gene cotransfected-macrophages by intratumoral injection].
Lei H; Cao X; Yu Y
Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):174-7. PubMed ID: 10920999
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of spontaneous metastatic lung cancer with interleukin-12 gene-modified dendritic cells vaccine].
Chen JQ; Xiu QY; Shen C; Yan ZM
Ai Zheng; 2002 Dec; 21(12):1328-31. PubMed ID: 12520741
[TBL] [Abstract][Full Text] [Related]
30. Augmentation of antitumor effect of adenovirus-mediated CD suicide gene therapy by cotransfer of interleukin 2 gene in melanoma-bearing mice.
Ju DW; Cao X; Tao Q; Wang B; Chen G; Yu Y
Chin Med J (Engl); 1999 Feb; 112(2):162-5. PubMed ID: 11593586
[TBL] [Abstract][Full Text] [Related]
31. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma.
Kircheis R; Küpcü Z; Wallner G; Wagner E
Cytokines Cell Mol Ther; 1998 Jun; 4(2):95-103. PubMed ID: 9681248
[TBL] [Abstract][Full Text] [Related]
32. Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2.
Cao X; Zhang W; Gu S; Yu Y; Tao Q; Ye T
J Cancer Res Clin Oncol; 1995; 121(12):721-8. PubMed ID: 7499443
[TBL] [Abstract][Full Text] [Related]
33. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
34. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
35. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
36. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
Liu X; Zhang L; Zhang M; Ma Y; Xu X; Cai Y
Chin Med J (Engl); 2000 Feb; 113(2):167-71. PubMed ID: 11775545
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
Akiyama Y; Watanabe M; Maruyama K; Ruscetti FW; Wiltrout RH; Yamaguchi K
Gene Ther; 2000 Dec; 7(24):2113-21. PubMed ID: 11223993
[TBL] [Abstract][Full Text] [Related]
38. Retroviral-mediated transfer of genes encoding interleukin-2 and interleukin-12 into fibroblasts increases host antitumor responsiveness.
Govaerts AS; Guillaume T; André M; Bayat B; Feyens AM; Hawley TS; Fong AZ; Hawley RG; Symann M
Cancer Gene Ther; 1999; 6(5):447-55. PubMed ID: 10505855
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of different cytokines on the tumorigenicity and immunogenicity of murine tumors.
Chen YM; Tsai CM; Perng RP
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Nov; 62(11):807-16. PubMed ID: 10575810
[TBL] [Abstract][Full Text] [Related]
40. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
